JOSEPH EDELMAN
CIK 1164426 · last filed 2026-07-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$767.90M
Companies
49
Total Filings
204
Lifetime Open-Market Net
$1.78B
Filer Profile
Reported Address
C/O PERCEPTIVE ADVISORS LLC51 ASTOR PLACE, 10TH FLOOR
NEW YORK, NY 10003
Related Filers
PERCEPTIVE ADVISORS LLC — 449 joint filings, latest 2026-08-27
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD — 430 joint filings, latest 2026-08-27
Scott Bradley — 49 joint filings, latest 2008-06-19
Michael Cho — 40 joint filings, latest 2008-06-19
Perceptive Xontogeny Venture Fund, LP — 20 joint filings, latest 2025-02-21
Perceptive Credit Advisors, LLC — 9 joint filings, latest 2023-05-01
Perceptive LS (A), LLC — 7 joint filings, latest 2025-11-13
Perceptive Venture Advisors, LLC — 7 joint filings, latest 2022-12-06
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FRNM | 10%+ Owner | 10,871,847 | — | — | $0 | 1 | 2026-07-22 |
| LONA | Director | — | $6.92 | — | $0 | 4 | 2026-07-10 |
| SLDB | Director | 73,107 | $8.70 | $636.0K | $120.44M | 5 | 2026-03-11 |
| LeonaBio, Inc. (ATHA) Delisted | Director | 329,756 | $6.92 | $2.28M | $51.30M | 9 | 2025-12-23 |
| ADGM | 10%+ Owner | — | $0.56 | — | $0 | 1 | 2025-10-22 |
| ACRV | 10%+ Owner | 3,104,139 | $2.00 | $6.21M | $48.71M | 3 | 2025-05-01 |
| ALDX | 10%+ Owner | 5,875,851 | $1.34 | $7.87M | $179.12M | 22 | 2025-04-07 |
| MGTX | Director | 12,531,103 | $12.79 | $160.27M | $15.00M | 3 | 2024-08-14 |
| Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Director | 10,794,876 | $44.96 | $485.34M | $60.00M | 2 | 2024-02-21 |
| VRCA | 10%+ Owner | 709,918 | $4.91 | $3.49M | $27.74M | 2 | 2023-12-29 |
| CARGO Therapeutics, Inc. (CRGX) Delisted | 2,579,502 | $4.47 | $11.53M | $40.00M | 1 | 2023-11-14 | |
| Astria Therapeutics, Inc. (ATXS) Delisted | Director | 1,652,371 | $12.58 | $20.79M | $28.00M | 1 | 2023-10-18 |
| SOLENO THERAPEUTICS INC (SLNO) Delisted | 10%+ Owner | 2,056,955 | $53.01 | $109.04M | $3.13M | 3 | 2023-06-01 |
| VBI Vaccines Inc/BC (VBIV) Delisted | 10%+ Owner | 1,523,061 | $0.07 | $99.5K | $64.91M | 8 | 2023-04-06 |
| Quotient Ltd (QTNT) Delisted | 10%+ Owner | 198,630 | $0.38 | $75.5K | $98.23M | 5 | 2022-11-02 |
| ALBIREO PHARMA, INC. (ALBO) Delisted | 10%+ Owner | 2,216,074 | $44.15 | $97.84M | -$28.52M | 1 | 2022-10-13 |
| LianBio (LIAN) Delisted | Director | 4,330,675 | $0.32 | $1.38M | $1.73M | 1 | 2022-05-27 |
| CRNX | 10%+ Owner | 5,321,032 | $84.95 | $452.02M | $96.78M | 3 | 2022-04-18 |
| AGILE THERAPEUTICS INC (AGRX) Delisted | 10%+ Owner | 10,827 | $1.51 | $16.3K | $48.35M | 7 | 2021-10-15 |
| IsoPlexis Corp (ISO) Delisted | 10%+ Owner | 2,704,587 | $0.76 | $2.06M | $76.50M | 1 | 2021-10-14 |
| RAIN | 10%+ Owner | 2,503,676 | $0.74 | $1.85M | $26.05M | 2 | 2021-10-13 |
| ADMA | 10%+ Owner | 13,262,375 | $9.23 | $122.41M | $45.33M | 5 | 2021-09-30 |
| CYPHERPUNK TECHNOLOGIES INC. (LPTX) Delisted | 10%+ Owner | 847,650 | $1.56 | $1.32M | $10.50M | 2 | 2021-09-28 |
| Landos Biopharma, Inc. (LABP) Delisted | Director | 719,830 | $22.93 | $16.51M | $16.06M | 2 | 2021-08-31 |
| Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | Director | 5,086,727 | $18.07 | $91.92M | $20.67M | 2 | 2021-08-31 |
| VYNE Therapeutics Inc. (VYNE) Delisted | 10%+ Owner | 5,483 | $28.56 | $156.6K | $14.04M | 5 | 2021-08-18 |
| NAUT | 6,494,076 | $1.02 | $6.62M | $165.21M | 1 | 2021-06-11 | |
| Nautilus Biotechnology, Inc. (ARYA) Delisted | Director | 489,975 | $11.16 | $5.47M | $14.77M | 2 | 2021-06-03 |
| Prometheus Biosciences, Inc. (RXDX) Delisted | 10%+ Owner | 3,314,032 | $199.92 | $662.54M | $48.45M | 1 | 2021-03-16 |
| SCYX | 10%+ Owner | 276,875 | $4.84 | $1.34M | -$14.12M | 1 | 2021-01-26 |
| Cerevel Therapeutics Holdings, Inc. (CATB) Delisted | Director | 19,017 | $8.54 | $162.4K | $4.73M | 1 | 2020-10-22 |
| Athenex, Inc. (ATNX) Delisted | 10%+ Owner | 676,623 | $0.20 | $137.4K | $175.18M | 14 | 2020-09-14 |
| Lyra Therapeutics, Inc. (LYRA) Delisted | Director | 26,182 | $0.70 | $18.3K | $0 | 1 | 2020-05-06 |
| Kadmon Holdings, Inc. (KDMN) Delisted | 10%+ Owner | 14,636,334 | $9.50 | $139.05M | $15.00M | 1 | 2019-11-18 |
| Dova Pharmaceuticals Inc. (DOVA) Delisted | 10%+ Owner | 3,708,705 | — | — | $49.99M | 10 | 2019-07-11 |
| Motus GI Holdings, Inc. (MOTS) Delisted | 10%+ Owner | 14,035 | $0.00 | $1 | $9.00M | 2 | 2019-07-01 |
| Corium International, Inc. (CORI) Delisted | 10%+ Owner | 5,574,686 | — | — | -$81.53M | 3 | 2018-10-15 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | 10%+ Owner | 20,694,424 | $14.49 | $299.86M | $185.21M | 16 | 2018-10-05 |
| ZOGENIX, INC. (ZGNX) Delisted | 10%+ Owner | 4,070,357 | $26.68 | $108.60M | $45.08M | 3 | 2018-08-14 |
| LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | 10%+ Owner | 3,613,611 | $6.22 | $22.48M | $4.86M | 1 | 2018-02-20 |
| Global Blood Therapeutics, Inc. (GBT) Delisted | 10%+ Owner | 4,889,066 | $68.49 | $334.85M | $19.95M | 1 | 2017-12-19 |
| Aravive, Inc. (VSAR) Delisted | 10%+ Owner | 624,927 | — | — | $2.93M | 7 | 2017-09-25 |
| TALPHERA, INC. (ACRX) Delisted | 10%+ Owner | 226,686 | $0.86 | $194.9K | -$16.83M | 5 | 2017-06-21 |
| REPROS THERAPEUTICS INC. (RPRX.Z) Delisted | 10%+ Owner | — | — | — | $0 | 1 | 2013-01-30 |
| Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | 10%+ Owner | 2,615,293 | — | — | $3.32M | 2 | 2012-12-05 |
| REPROS THERAPEUTICS INC. (RPRXZ) Delisted | 10%+ Owner | 2,862,560 | — | — | $9.26M | 3 | 2012-05-15 |
| XTLB | 10%+ Owner | 0 | $2.56 | $0 | $74.18M | 7 | 2008-12-03 |
| PENWEST PHARMACEUTICALS CO (PPCO) Delisted | 10%+ Owner | 6,422,846 | — | — | $39.96M | 12 | 2008-11-06 |
| IDEV | 10%+ Owner | 56,300 | $91.88 | $5.17M | -$36.60M | 1 | 2007-01-05 |
Recent Filings · Page 13 of 21
204 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-09-17 | AMICUS THERAPEUTICS, INC. (FOLD) Delisted | Buy (P) | +300,000 | $3.52M | EDGAR |
| 2018-09-14 | AMICUS THERAPEUTICS, INC. (FOLD) Delisted | Buy (P) | +1,500,000 | $18.00M | EDGAR |
| 2018-08-14 | ZOGENIX, INC. (ZGNX) Delisted | Buy (P) | +300,000 | $15.60M | EDGAR |
| 2018-07-26 | AGILE THERAPEUTICS INC (AGRX) Delisted | Sell (S) | −895,884 | -$268.3K | EDGAR |
| 2018-07-20 | Quotient Ltd (QTNT) Delisted | Exer (X) | +6,918,102 | $40.12M | EDGAR |
| 2018-06-13 | Dova Pharmaceuticals Inc. (DOVA) Delisted | Buy (P) | +59,100 | $1.74M | EDGAR |
| 2018-06-12 | Dova Pharmaceuticals Inc. (DOVA) Delisted | Buy (P) | +75,000 | $2.15M | EDGAR |
| 2018-06-11 | Dova Pharmaceuticals Inc. (DOVA) Delisted | Buy (P) | +150,000 | $4.23M | EDGAR |
| 2018-06-08 | Dova Pharmaceuticals Inc. (DOVA) Delisted | Buy (P) | +300,000 | $8.60M | EDGAR |
| 2018-06-07 | Dova Pharmaceuticals Inc. (DOVA) Delisted | Buy (P) | +300,000 | $7.80M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.